Deals like these can attract criticism from consumer advocates and some regulators over concerns they lead to higher ...
Deals like these can attract criticism from consumer advocates and some regulators over concerns they lead to higher ...
Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...
Discover Essential Utilities’ Q3 2025 earnings: insights on the American Water merger, growth projections, data center investments & robust financial results.
News, how-tos, features, reviews, and videos ...
Oakmark spotlights six stocks driving AI, M&A, and analytics upside, while navigating debt, guidance cuts, and valuation ...
2don MSN
Concurrent’s Nate Lenz on Soaring RIA Valuations and the Benefits of Selling a Minority Stake
The 36-year-old founder of one of the fastest growing hybrid RIAs talks about how founders can start to cash out of their ...
Detailed price information for Trump Media & Technology Group Corp (DJT-Q) from The Globe and Mail including charting and trades.
Q3 2025 Management View CEO David Spreng highlighted the completion of a definitive merger agreement to acquire SWK Holdings, ...
ALLY Robotic Cataract Laser Systems® ('ALLY Systems”) placed in 3Q 2025; Backlog of 18 ALLY Systems pending installation as of September 30, 2025 ...
Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback